Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more
Avalo Therapeutics Inc (AVTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.179x
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has a cash flow conversion efficiency ratio of -0.179x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($91.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Avalo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Avalo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Valuetronics Holdings Limited
F:GJ7
|
0.021x |
|
SEACOR Marine Holdings Inc
NYSE:SMHI
|
-0.038x |
|
Qinghaihuading Industrial Co Ltd
SHG:600243
|
-0.009x |
|
Dasheng Times Cultural Investment Co Ltd
SHG:600892
|
-6.385x |
|
Beijing North Star Company Limited
PINK:BEIJF
|
0.041x |
|
Omai Gold Mines Corp
OTCQB:OMGGF
|
-0.077x |
|
Wenzhou Yuanfei Pet Toy Products Co. Ltd. A
SHE:001222
|
0.030x |
|
Compugen
NASDAQ:CGEN
|
-0.526x |
Annual Cash Flow Conversion Efficiency for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Avalo Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $133.03 Million | $-49.06 Million | -0.369x | +91.22% |
| 2023-12-31 | $7.30 Million | $-30.68 Million | -4.200x | -271.39% |
| 2022-12-31 | $-10.91 Million | $-26.75 Million | 2.451x | +179.80% |
| 2021-12-31 | $23.08 Million | $-70.89 Million | -3.071x | -86.09% |
| 2020-12-31 | $24.56 Million | $-40.54 Million | -1.650x | -81.10% |
| 2019-12-31 | $21.00 Million | $-19.13 Million | -0.911x | -509.13% |
| 2018-12-31 | $20.91 Million | $-3.13 Million | -0.150x | -133.29% |
| 2017-12-31 | $27.86 Million | $12.52 Million | 0.449x | +100.64% |
| 2016-12-31 | $207.00K | $-14.57 Million | -70.402x | -8963.27% |
| 2015-12-31 | $13.08 Million | $-10.16 Million | -0.777x | -231.80% |
| 2014-12-31 | $-26.33 Million | $-15.52 Million | 0.589x | -8.42% |
| 2013-12-31 | $-17.85 Million | $-11.49 Million | 0.644x | +158.73% |
| 2012-12-31 | $8.48 Million | $-9.29 Million | -1.096x | -- |